483
U.S. Investigational Review Board Inc.U.S. Investigational Review Board Inc. – FDA 483, Jun 6, 2022
Record Details
An FDA inspection of U.S. Investigational Review Board Inc. in Miami, FL, revealed significant deficiencies in its Institutional Review Board operations. Findings included inadequate meeting minutes, improper use of expedited review for studies involving more than minimal risk, and failure to advise IRB members of expedited approvals. Additionally, the firm did not report changes to the types of FDA-regulated products it reviews within the required timeframe.
View Company Profile
ID · 97aa7ac9-897b-4abd-9f69-de66fe4b82a6
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.